Xenon Pharmaceuticals fell about 25% to $42.84 in Friday premarket, against Thursday's $57.35 close — its worst single day since March 2017, per CoinCentral. It went in with a $5.6bn market cap after a 52% gain over the prior year.

The trigger landed after Thursday's bell. Xenon voluntarily paused new patient enrolment in its psychiatry programme for azetukalner after reviewing neuropsychiatric adverse events — reported as confusion, somnolence, ataxia and rare cases of psychosis. That covers three Phase 3 X-NOVA studies in major depression (~450 patients each) and two Phase 3 X-CEED studies in bipolar depression (~400 each). Patients already enrolled stay on. The company said the events' rate and severity were consistent with azetukalner's known profile, but acknowledged they hadn't shown up in the earlier Phase 2 X-NOVA study.

Why a pause, not a halt, still cost a quarter of the company

Two things happened the same day and they pull opposite ways — don't blend them.

• Epilepsy is untouched. Xenon filed its NDA for azetukalner in focal seizures, on Phase 2b X-TOLE and Phase 3 X-TOLE2 data where all four doses cut monthly seizure frequency versus placebo, backed by over 1,500 patient-years of safety exposure. Those trials keep enrolling.
• Psychiatry is where the option value was. Depression is the far bigger market, and it's frozen until data. X-NOVA2 had already closed enrolment at roughly 360 of 450 patients (~80%), topline due Q1 2027.

So the market didn't reprice the epilepsy drug. It repriced the depression call option — and the notes show the split. Deutsche Bank cut Buy to Hold, target $90 to $46, saying the events "impair the molecule's overall profile as a potential best-in-class drug" and openly disagreeing with management's read. Needham stayed Buy but cut $78 to $60. Stifel held Buy at $86, arguing the stock trades with "minimal option value for neuropsychiatric indications" until Q1 2027, and pointing at Keppra — past $2bn peak sales despite its own neuropsychiatric warnings. That $46-to-$86 spread is the whole argument in one range.

The ripple: the clearest read-through is Axsome Therapeutics, whose Auvelity is the incumbent novel-mechanism MDD product. Azetukalner was the credible next challenger for that slot; a paused Phase 3 programme pushes any competing launch out by at least the length of the delay, so Axsome keeps the field to itself for longer.

What flips it: the Q1 2027 X-NOVA2 topline. It's already fully enrolled, so it lands regardless of the pause — clean efficacy and the psychiatry option is back on the board; a weak print and Deutsche Bank's $46 becomes the anchor, not the floor. Sooner: the FDA's acceptance decision on the focal-seizure NDA, which is what turns Xenon into a company with a product. More movers here.

As of 18 Sep 2026, 10:15 am ET / 7:45 pm IST. Sources: Investing.com, RTTNews, Investing.com (Deutsche Bank), Investing.com (Stifel), CoinCentral. For discussion and education only — not investment advice. Verify before acting.